Clinical Trials Logo

Immunocompromised Patients clinical trials

View clinical trials related to Immunocompromised Patients.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05726006 Recruiting - Diabetic Foot Clinical Trials

Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults.

Start date: February 1, 2020
Phase:
Study type: Observational

Group B Streptococcus (GBS) infection is a potential aetiology of meningitis and septicemia in neonates, pregnant women and non-pregnant adults. Because the GBS disease burden is unknown in Malaysia, it is unlikely to receive much attention. This study aims to determine the prevalence of group B streptococcus isolated from non-pregnant adults, the Incidence, case-fatality ratio, antimicrobial susceptibility patterns, serotyping, genotyping and detection of the GBS virulence and pili genes from six major hospitals in Peninsular Malaysia.

NCT ID: NCT05605145 Recruiting - Diagnosis Clinical Trials

PCP in Immunocompromised Population in Southern China

PCP
Start date: May 12, 2021
Phase:
Study type: Observational

To evaluate the sensitivity and specificity of the combined detection system for the diagnosis of pneumocystis infection in immunocompromised population in Southern China.

NCT ID: NCT05439044 Recruiting - Clinical trials for Immunocompromised Patients

A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies

COVIMAB
Start date: March 1, 2020
Phase:
Study type: Observational

Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients. Being at high risk of a severe form of Covid-19, they may be eligible to receive recombinant anti-SARS-CoV-2 monoclonal antibodies (mAbs). This study aims to describe patients who received anti-SARS-CoV-2 mAbs, in prophylaxis and/or curative of covid-19, and to analyze the hospitalization and mortality rates. This study is multicentric on all the university hospitals of Paris (AP-HP).